Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 150 av 222 resultater
Tid
Selskap
Tittel
Sektor
Kategori
27 Mar 2023
22:15 CEST
NANOBIOTIX
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
20103010 Biotechnology
Legal
27 Mar 2023
22:15 CEST
NANOBIOTIX
Nanobiotix reporte la publication de ses résultats financiers de l'exercice 2022 et la confé֤rence téléphonique
20103010 Biotechnology
Legal
14 Mar 2023
21:15 CET
NANOBIOTIX
Nanobiotix publiera le 28 mars 2023 ses résultats financiers de l'exercice 2022 et fera le point sur ses activités opérationnelles
20103010 Biotechnology
Other financial transaction
14 Mar 2023
21:15 CET
NANOBIOTIX
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
20103010 Biotechnology
Other financial transaction
14 Feb 2023
22:15 CET
NANOBIOTIX
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Change in Capital
14 Feb 2023
22:15 CET
NANOBIOTIX
Voting Rights and Shares Capital of the Company
20103010 Biotechnology
Change in Capital
11 Jan 2023
22:15 CET
NANOBIOTIX
Voting Rights and Shares Capital of the Company
20103010 Biotechnology
Change in Capital
11 Jan 2023
22:15 CET
NANOBIOTIX
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Change in Capital
27 Dec 2022
07:45 CET
NANOBIOTIX
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
20103010 Biotechnology
Corporate life
27 Dec 2022
07:45 CET
NANOBIOTIX
NANOBIOTIX annonce la randomisation du premier patient aux États-Unis dans l’essai pivot mondial de Phase 3 évaluant le radioenhancer NBTXR3 dans le cancer de la tête et du cou
20103010 Biotechnology
Corporate life
21 Dec 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX ANNONCE LA RÉSILIATION DE SON CONTRAT DE LIQUIDITÉ ET PRÉSENTE LE BILAN DE FIN DE CONTRAT
20103010 Biotechnology
Legal
08 Dec 2022
22:15 CET
NANOBIOTIX
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Corporate life
15 Nov 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX participera à la 5ème Evercore ISI HealthCONx Conference
20103010 Biotechnology
Corporate life
14 Nov 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX annonce la détermination de la dose recommandée pour la Phase 2 de NBTXR3 dans le traitement du cancer du pancréas
20103010 Biotechnology
Corporate life
10 Nov 2022
08:00 CET
NANOBIOTIX
37ème réunion annuelle de la Society for Immunotherapy of Cancer (SITC) : NANOBIOTIX présente des données de phase 1 actualisées sur la combinaison de NBTXR3 avec un anti-PD-1, qui pourraient soutenir le potentiel de stimulation du système immuni...
20103010 Biotechnology
Corporate life
09 Nov 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le troisième trimestre 2022
20103010 Biotechnology
Commercial results
08 Nov 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Change in Capital
02 Nov 2022
21:15 CET
NANOBIOTIX
NANOBIOTIX nomme des experts de premier plan afin de former son conseil scientifique consultatif pour NBTXR3, son radioenhancer potentiel first-in-class
20103010 Biotechnology
Corporate life
31 Oct 2022
21:15 CET
NANOBIOTIX
NANOBIOTIX participera à la Jefferies Healthcare Conference à Londres
20103010 Biotechnology
Meetings / events
27 Oct 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX annoncera le 9 novembre 2022, ses resultats financiers pour le troisieme trimestre 2022
20103010 Biotechnology
Corporate life
18 Oct 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX conclut un accord définitif pour la restructuration du prêt octroyé par la Banque européenne d’investissement
20103010 Biotechnology
News contracts
10 Oct 2022
22:15 CEST
NANOBIOTIX
Nanobiotix: Voting Rights and Shares Capital of the Company
20103010 Biotechnology
Other subject
10 Oct 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
28 Sep 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER SEMESTRE 2022
20103010 Biotechnology
Commercial results
28 Sep 2022
22:15 CEST
NANOBIOTIX
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
20103010 Biotechnology
Commercial results
22 Sep 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX ANNONCERA LE 28 SEPTEMBRE 2022, SES RÉSULTATS FINANCIERS POUR LE PREMIER SEMESTRE 2022
20103010 Biotechnology
Other subject
22 Sep 2022
22:15 CEST
NANOBIOTIX
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
20103010 Biotechnology
Other subject
21 Sep 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX ÉTABLIT LA DOSE RECOMMANDÉE POUR L’ÉTUDE D’ENREGISTREMENT ÉVALUANT L’ASSOCIATION NBTXR3 + ANTI-PD-1 CHEZ DES PATIENTS ATTEINTS DE CANCER MÉTASTATIQUE DE LA TÊTE ET DU COU ET RÉSISTANT À L’IMMUNOTHÉRAPIE
20103010 Biotechnology
Other subject
21 Sep 2022
22:15 CEST
NANOBIOTIX
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
20103010 Biotechnology
Other subject
12 Sep 2022
08:00 CEST
NANOBIOTIX
NANOBIOTIX ANNONCE UN ACCORD DE PRINCIPE POUR RESTRUCTURER L’ACCORD DE PRÊT EXISTANT AVEC LA BANQUE EUROPÉENNE D’INVESTISSEMENT, PROLONGEANT AINSI LA CAPACITE OPERATIONELLE DE LA SOCIÉTÉ JUSQU’AU 1er TRIMESTRE 2024.
20103010 Biotechnology
Other subject
12 Sep 2022
08:00 CEST
NANOBIOTIX
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
20103010 Biotechnology
Other subject
08 Sep 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
08 Sep 2022
22:15 CEST
NANOBIOTIX
Nanobiotix: Voting Rights and Shares Capital of the Company
20103010 Biotechnology
Other subject
07 Sep 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
20103010 Biotechnology
Other subject
07 Sep 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX ET LIANBIO ANNONCENT LE RECRUTEMENT DU PREMIER PATIENT EN ASIE POUR L’ESSAI DE PHASE 3 NANORAY-312, ÉVALUANT NBTXR3 DANS LA PRISE EN CHARGE DES CANCERS DE LA TÊTE ET DU COU
20103010 Biotechnology
Other subject
06 Sep 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
20103010 Biotechnology
Other subject
06 Sep 2022
22:15 CEST
NANOBIOTIX
LAURENT LEVY, CO-FONDATEUR ET PRÉSIDENT DU DIRECTOIRE DE NANOBIOTIX, A ÉTÉ DESIGNÉ POUR APPARAÎTRE SUR LA LISTE PHARMAVOICE 100 DES PERSONNES LES PLUS INSPIRANTES DU SECTEUR DES SCIENCES DE LA VIE EN 2022
20103010 Biotechnology
Other subject
31 Aug 2022
22:15 CEST
NANOBIOTIX
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
20103010 Biotechnology
Meetings / events
31 Aug 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX PARTICIPERA À LA CONFÉRENCE INTERNATIONALE INVESTISSEURS DE H.C. WAINWRIGHT AU MOIS DE SEPTEMBRE 2022
20103010 Biotechnology
Meetings / events
09 Aug 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
09 Aug 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX: Voting Rights and Shares Capital of the Company
20103010 Biotechnology
Other subject
13 Jul 2022
22:15 CEST
NANOBIOTIX
BILAN SEMESTRIEL 2022 DU CONTRAT DE LIQUIDITÉ NANOBIOTIX AVEC LA SOCIÉTÉ DE BOURSE GILBERT DUPONT
20103010 Biotechnology
Other subject
13 Jul 2022
22:15 CEST
NANOBIOTIX
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
20103010 Biotechnology
Other subject
08 Jul 2022
22:15 CEST
NANOBIOTIX
Nanobiotix : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Commercial results
08 Jul 2022
22:15 CEST
NANOBIOTIX
Nanobiotix: Voting Rights and Shares Capital of the Company
20103010 Biotechnology
Commercial results
09 Jun 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
09 Jun 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
05 Jun 2022
15:00 CEST
NANOBIOTIX
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
20103010 Biotechnology
Other subject
05 Jun 2022
15:00 CEST
NANOBIOTIX
NANOBIOTIX :DE NOUVELLES DONNÉES ASSOCIANT NBTRX3 AVEC LA CHIMIOTHÉRAPIE EN PRÉOPÉRATOIRE INDIQUENT QUE NBTRX3 S’INTEGRERAIT DANS LE TRAITEMENT DU CANCER DE LA TÊTE ET DU COU ET D'AUTRES TUMEURS SOLIDES
20103010 Biotechnology
Other subject
02 Jun 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva